Patents by Inventor Patrick Michael Hossler

Patrick Michael Hossler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMMERCIAL-SCALE RECOMBINANT PROTEIN PRODUCTION IN RAT HYBRIDOMA CELLS
    Publication number: 20260062495
    Abstract: The present disclosure relates to methods of making recombinant proteins (e.g., monoclonal antibodies) in rat hybridoma cells (e.g., YB2/0) with high productivity, product quality, and robust functional activity by modifying cell culture process parameters and/or basal media and feed combinations. The present disclosure also relates to commercial-scale production (e.g., 10,000 L-25,000 L) of recombinant proteins (e.g., monoclonal antibodies) in rat hybridoma cells. The present disclosure also relates to recombinant proteins (e.g., monoclonal antibodies) and compositions (e.g., pharmaceutical) that are made using the methods disclosed herein, and which have a unique glycosylation profile.
    Type: Application
    Filed: May 31, 2023
    Publication date: March 5, 2026
    Inventors: George Costas AVGERINOS, Patrick Michael HOSSLER
  • ANTI-CD20 ANTIBODY COMPOSITIONS
    Publication number: 20240270863
    Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.
    Type: Application
    Filed: March 6, 2024
    Publication date: August 15, 2024
    Inventors: George Costas Avgerinos, Patrick Michael Hossler, Jill A. Myers, Yune Z. Kunes
  • ANTI-CD20 ANTIBODY COMPOSITIONS
    Publication number: 20240209110
    Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.
    Type: Application
    Filed: March 6, 2024
    Publication date: June 27, 2024
    Inventors: George Costas Avgerinos, Patrick Michael Hossler, Jill A. Myers, Yune Z. Kunes
  • Anti-CD20 antibody compositions
    Patent number: 11965032
    Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.
    Type: Grant
    Filed: February 10, 2023
    Date of Patent: April 23, 2024
    Assignees: TG Therapeutics, Inc., Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: George Costas Avgerinos, Patrick Michael Hossler, Jill A. Myers, Yune Z. Kunes
  • Anti-CD20 antibody compositions
    Patent number: 11884740
    Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: January 30, 2024
    Assignees: TG Therapeutics, Inc., Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: George Costas Avgerinos, Patrick Michael Hossler, Jill A. Myers, Yune Z. Kunes
  • Anti-CD20 antibody compositions
    Patent number: 11814439
    Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: November 14, 2023
    Assignees: TG Therapeutics, Inc., Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: George Costas Avgerinos, Patrick Michael Hossler, Jill A. Myers, Yune Z. Kunes, Sri Hari Pandurang Miskin, Michael Weiss, Peter Sportelli
  • Anti-CD20 antibody compositions
    Patent number: 11807689
    Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: November 7, 2023
    Assignees: TG Therapeutics, Inc., Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: George Costas Avgerinos, Patrick Michael Hossler, Jill A. Myers, Yune Z. Kunes